

Exhibit C

UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

If you purchased and/or paid for some or all of the price of Suboxone from December 22, 2011 through August 21, 2023,

***You Could Get a Payment from a Class Action Lawsuit.
A Federal Court Ordered this Class Notice.***

YOUR LEGAL RIGHTS MAY BE AFFECTED WHETHER YOU ACT OR DO NOT ACT, SO PLEASE READ THIS NOTICE CAREFULLY.

This is not a solicitation from a lawyer. You are not being sued.

The purpose of this Notice is to alert you to a proposed settlement in a lawsuit pending in the Eastern District of Pennsylvania (the “Court”) against Indivior, Inc. (“Indivior” or “Defendant”), in connection with Defendant’s manufacture and marketing of the opioid addiction treatment drug (Co-Formulated Buprenorphine/Naloxone). Plaintiffs in the lawsuit allege that Indivior hurt competition and violated state antitrust, consumer protection, and unjust enrichment laws in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, and District of Columbia (the “Settled States”) between December 22, 2011 and August 21, 2023 (the “Class Period”). As a result, the lawsuit claims consumers and third-party payors (defined below) paid too much for Suboxone, brand and generic, in these states. Defendant denies that it violated any laws.

The lawsuit does not claim that Suboxone or its generic equivalents are harmful in any way.

The Court previously determined that, based on the Plaintiffs’ motion, the lawsuit could proceed as a class action for litigation on behalf of a “Class,” or group of people and entities, for purchases of Suboxone made in eleven (11) states and confined to an element of establishing antitrust liability (the “11-State Class”). Plaintiffs did not request, and the Court did not certify, a damages class.

After additional litigation through the denial of Defendant’s motion for summary judgment, the parties reached a \$30 million settlement (the “Settlement”) with respect to the claims made for *all* the foregoing Settled States. The Court has preliminarily approved the Settlement and certified a Class for the purchases made in the Settled States pursuant to Rule 23(b)(3) of the Federal Rules of Civil Procedure. The purpose of this notice is to tell you your rights under the Settlement if you are a member of the certified settlement class (the “End Payor Class”).

You are a member of the End Payor Class if:

- As a Third-Party Payer (“TPP”), you paid all or part of the purchase price for Suboxone tablets, Suboxone film, or AB-rated generic equivalents of Suboxone (generic Suboxone) in any one of the Settled States during the Class Period.
- As a Consumer, you paid all or part of the purchase price for Suboxone tablets, Suboxone film, or AB-rated generic equivalents of Suboxone (generic Suboxone) in any one of the Settled States during the Class Period.
- Only TPPs and consumers that made these purchases and are not excluded as set forth below during the Class Period are included in the End Payor Class.
- The Class Period begins on December 22, 2011 and ends on August 21, 2023.

You are excluded from the End Payor Class -- meaning you are not in the End Payor Class – if you are in any of the following categories.

QUESTIONS? CALL 877-311-3735 OR VISIT WWW.SUBOXANTITRUST.COM.

- Pharmacy benefit managers;
- Defendant and its officers, directors, management, employees, subsidiaries, or affiliates;
- All governmental entities, except for government funded employee benefit plans;
- All persons or entities who purchased Suboxone and/or its AB-rated generic equivalent in any form for purposes of resale or directly from Defendant or its affiliates; and
- The judges in this case and any members of their immediate families.

The Settlement provides for Indivior's payment of \$30 million into a Settlement Fund for distribution to End Payor Class members submitting valid claim forms, attorneys' fees, the expenses of litigation (including costs of Notice), and service awards to the named Plaintiffs, all of which is subject to final approval by the Court. The Court has scheduled a hearing (the "Fairness Hearing") to consider whether to grant such final approval. The Fairness Hearing is scheduled for October 19, 2023, at 1:30 p.m., before Judge Mitchell S. Goldberg at the James A. Byrne U.S. Courthouse, 601 Market Street, Philadelphia, PA 19106.

There are decisions you must make regarding your participation in the Settlement. Please consider the information in this Notice carefully as you do so.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS LAWSUIT	
DO NOTHING	If you are a member of the End Payor Class and want to remain a member of the End Payor Class, you are not required to do anything. To recover anything, however, you must submit a Claim Form as described immediately below. You will be bound by any decision of the Court in this lawsuit, including rulings on the Settlement. <i>See Question 11.</i>
SUBMIT A CLAIM FORM	If you did not exclude yourself from the End Payor Class prior to the April 17, 2022 deadline and believe you are an End Payor Class Member, and want to participate in the distribution of the Net Settlement Fund, you will need to complete and return a Claim Form to obtain a share of the Settlement Fund. The Claim Form, and information on how to submit it, are available on the Settlement website. Consumer identities will not be made public during any part of the claims process. Claim Forms must be postmarked (if mailed) or received (if submitted online) on or before February 17, 2024 . <i>See Question 7</i> for more information.
EXCLUDE YOURSELF FROM THE END PAYOR CLASS	This option allows you to exclude yourself from the End Payor Class and retain the right to file a lawsuit against Indivior asserting the claims relating to the allegations in this case. If you exclude yourself, you will not share in any money from the Settlement. The exclusion deadline is October 12, 2023 . Consumer identities will not be made public during any part of the exclusion process.

QUESTIONS? CALL 877-311-3735 OR VISIT WWW.SUBOXANTITRUST.COM.

OBJECT TO THE SETTLEMENT OR SPEAK AT THE FAIRNESS HEARING	If you object to all or any part of the Settlement, request for attorneys' fees, reimbursement of expenses, or service awards to the class representatives, or desire to speak in person at the Fairness Hearing, you must file a written letter of objection and/or a notice of intention to speak along with a summary statement with the Court and with Co-Lead Counsel and counsel for the Defendant by October 5, 2023 . <i>See Question 13.</i> Consumer identities will not be made part of public record without consent during the objections process.
GET MORE INFORMATION	If you would like more information about the lawsuit, you can review this Notice and send questions to the Settlement Administrator and/or Co-Lead Counsel. <i>See Question 21.</i> DO NOT CONTACT THE COURT OR THE DEFENDANT IF YOU HAVE QUESTIONS REGARDING THIS NOTICE.

This Notice incorporates by reference the definitions in the Settlement Agreement. The Settlement Agreement and the Court's Preliminary Approval Order are posted on the website, www.SuboxAntitrust.com. All capitalized terms used, but not defined, shall have the same meanings as in the Settlement Agreement and the Court's Preliminary Approval Order.

BASIC INFORMATION..... 5

1. Why did I receive this Notice?..... 5
2. What is the lawsuit about? 5
3. Why is this lawsuit a class action? 5
4. Why is there a Settlement with Defendant?..... 6

WHO CAN PARTICIPATE IN THE SETTLEMENT?..... 6

5. Am I part of the End Payor Class?..... 6

THE SETTLEMENT BENEFITS..... 7

6. What does the Settlement with the Defendant provide? 7

HOW YOU GET A PAYMENT: SUBMITTING A CLAIM FORM..... 7

7. How can I get a payment?..... 7
8. How much will my payment be? 8
9. When would I get my payment? 8

EXCLUDING YOURSELF FROM THE END PAYOR CLASS 8

10. What does it mean to request to be excluded from the End Payor Class..... 8
11. How do I exclude myself from the End Payor Class? 8
12. If I don't exclude myself, can I sue for an antitrust violation later? 8

OBJECTING TO THE SETTLEMENT 9

13. How do I tell the Court what I think about the Settlement? 9

QUESTIONS? CALL 877-311-3735 OR VISIT WWW.SUBOXANTITRUST.COM.

IF YOU DO NOTHING	10
14. <u>What happens if I do nothing at all?</u>	10
THE LAWYERS REPRESENTING THE END PAYOR CLASS	10
15. <u>Do I have a lawyer in this case?</u>	10
16. <u>Should I hire my own lawyer?</u>	10
17. <u>How will the lawyers be paid?</u>	10
THE FAIRNESS HEARING	11
18. <u>When and where will the Court decide whether to approve the Settlement?</u>	11
19. <u>Do I have to come to the hearing?</u>	11
20. <u>May I speak at the hearing?</u>	11
GETTING MORE INFORMATION.....	12
21. <u>Are more details available?</u>	12

BASIC INFORMATION

1. Why did I receive this Notice?

A federal court authorized this Notice because you may be part of the certified End Payor Class and, if so, to tell you about your options under the proposed Settlement. This Notice explains the lawsuit and the Settlement; describes the certified End Payor Class whose rights may be affected by the Settlement; and explains your legal rights. Note that you may have received this Notice in error; simply receiving this Notice does not mean that you are definitely a member of the End Payor Class. You may confirm that you are a member of the End Payor Class by reviewing the criteria set forth in **Question 5** below. You may also call, email, or write to the lawyers in this case at the telephone numbers or addresses listed in **Question 15** below.

2. What is the lawsuit about?

Plaintiffs in this lawsuit claim that Indivior violated certain state antitrust, consumer protection, and unjust enrichment laws in the United States (except Indiana and Ohio), the District of Columbia, and Puerto Rico, harming competition and causing End Payor Class members to overpay for Suboxone. Indivior denies that they violated any laws. The litigation is proceeding and, at this point, the court has not ruled on whether Indivior engaged in the wrongdoing alleged.

Following the completion of fact discovery, expert discovery, class certification, summary judgment motions, and motions determining the admissibility of expert testimony, and following extensive negotiations, End Payor Plaintiffs, individually and on behalf of the End Payor Class, entered into the Settlement with Indivior. The Settlement Agreement is available for review on the Settlement website. The Settlement is not an admission of wrongdoing by Defendant or an admission by End Payor Plaintiffs of any lack of merit in their claims.

THE COURT HAS NOT DECIDED WHETHER INDIVIOR VIOLATED ANY LAWS. THIS NOTICE IS NOT AN EXPRESSION OF ANY OPINION BY THE COURT AS TO THE MERITS OF PLAINTIFFS' CLAIMS OR THE DEFENSES ASSERTED BY INDIVIOR.

3. Why is this lawsuit a class action?

In a class action, one or more entities or persons called “class representatives” sue on behalf of other persons and entities with similar claims. In this case, the class representatives (referred to as the “End Payor Plaintiffs”) are A.F. of L. – A.G.C. Building Trades Welfare Plan, I.B.E.W. 292 Health Care Plan, Michigan Regional Council of Carpenters Employee Benefits Fund, Painters District Council No. 30 Health and Welfare Fund, Teamsters Health Services and Insurance Plan Local 404, Construction & General Laborers’ Local 190 Welfare Fund, and United Food and Commercial Workers Health and Welfare Fund of Northeastern Pennsylvania. The End Payor Plaintiffs and the entities on whose behalf they have sued together constitute the “End Payor Class.”

The company that has been sued is called the “Defendant.” In this case, the Defendant is Indivior plc. In a class action lawsuit, one court resolves the issues for everyone in the certified class, except for those class members who exclude themselves (*i.e.*, “opt out”) from the class. The Court, by Order dated August 21, 2023, preliminarily approved the Settlement and certified the End Payor Class as a settlement class, meaning the lawsuit between End Payor Plaintiffs and Defendant can proceed as a class action for purposes of the Settlement.

The case does not involve the safety or efficacy of Suboxone or its AB-rated generic equivalents.

QUESTIONS? CALL 877-311-3735 OR VISIT WWW.SUBOXANTITRUST.COM.

4. Why is there a Settlement with the Defendant?

The Settlement is the product of extensive negotiations between Co-Lead Counsel for the End Payor Class and counsel for the Defendant, with mediation and after lengthy, hard-fought litigation. At the time of the Settlement, discovery was complete, an 11-State Class had been certified for litigation, expert reports had been exchanged and experts examined, and motions for summary judgment and to determine the admissibility of expert testimony had been decided, and other motions were prepared and awaiting argument and/or decision. By settling, the End Payor Class and Defendant avoid the cost and risks of trial and possible appeals. For the End Payor Class, the Settlement, if approved by the Court, ensures that the End Payor Class members will receive compensation for damages arising from Defendant's alleged scheme to delay and impede the market entry of less expensive, generic versions of Suboxone. Co-Lead Counsel and the End Payor Plaintiffs believe that the terms of the Settlement, including payment by the Defendant of \$30 million in exchange for a release of End Payor Plaintiffs' and the End Payor Class's claims against the Defendant, are fair, reasonable, and adequate, and in the best interests of the End Payor Class.

WHO CAN PARTICIPATE IN THE SETTLEMENT?

To see if you are in the End Payor Class and, if so, how you will be able to share in the Settlement Fund, you need to determine whether you may be an End Payor Class member.

5. Am I part of the End Payor Class?

You may be a member of the End Payor Class if, during the period December 22, 2011 through August 21, 2023 (the "Class Period"), you indirectly purchased and/or paid for some or all of the purchase price for Co-Formulated Buprenorphine/Naloxone (Suboxone and/or its AB-rated generic equivalent) in any form, for consumption by themselves, their families or their members, employees, plan participants, beneficiaries, or insureds in, and not for resale, Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, and District of Columbia.

- The following are *NOT* members of the End Payor Class:
 - Pharmacy benefit managers;
 - Defendant and its officers, directors, management, employees, subsidiaries, or affiliates;
 - All governmental entities, except for government funded employee benefit plans;
 - All persons or entities who purchased Suboxone and/or its AB-rated generic equivalent in any form for purposes of resale or directly from Defendant or its affiliates; and
 - The judges in this case and any members of their immediate families.

Individuals and entities that submit or submitted a valid exclusion request on time are also excluded.

If you are not sure whether you are included in the End Payor Class, you may call, email, or write to the Settlement Administrator or lawyers in this case at the telephone numbers, email addresses, or addresses listed in **Question 15** below.

QUESTIONS? CALL 877-311-3735 OR VISIT WWW.SUBOXANTITRUST.COM.

THE SETTLEMENT BENEFITS

6. What does the Settlement with the Defendant provide?

The Defendant will, within fifteen (15) business days after the preliminary approval of the Settlement, pay \$30 million into an interest-bearing escrow account established by Co-Lead Counsel. The funds will be held in escrow for the benefit of the End Payor Class (including any interest that accrues) pending the Court's approval of the Settlement and Co-Lead Counsel's plan to distribute the Net Settlement Fund to eligible End Payor Class members.

If the Settlement is approved by the Court and becomes final, Co-Lead Counsel will seek approval from the Court to obtain from the Settlement Fund: (i) attorneys' fees for all class counsel of one-third of the Settlement Fund; (ii) reimbursement of reasonable costs and expenses incurred by all class counsel in connection with the litigation; and (iii) payment for service awards to the End Payor Plaintiffs in recognition of their efforts to date on behalf of the End Payor Class. Class Counsel may also seek additional attorneys' fees and reimbursement of expenses incurred during the course of claims administration. The remainder after payment of the above expenses and payment of any administration expenses (the "Net Settlement Fund") will be divided among End Payor Class members that timely return valid, approved claim forms pursuant to the Plan of Allocation available on the Settlement website.

In exchange, the End Payor Class's claims against Defendant will be dismissed with prejudice, and Defendant will be released by End Payor Class members not excluded from all claims concerning the subject matter of or acts, omissions, or other conduct alleged in the End Payor Plaintiffs' Second Consolidated Amended Class Action Complaint. The full text of the release is included in the Settlement Agreement available at www.SuboxAntitrust.com.

The Settlement may be terminated under the conditions set forth in the Settlement Agreement, paragraph 14. If the Settlement is terminated, the lawsuit will proceed against Defendant as if the Settlement had not been reached.

HOW YOU GET A PAYMENT: SUBMITTING A CLAIM FORM

7. How can I get a payment?

To be eligible to receive a payment if the Court approves the Settlement, all End Payor Class members must complete and submit a valid Claim Form to request their *pro rata* shares of the Net Settlement Fund. You will not be responsible for calculating the amount you are entitled to receive. If you are a consumer, your identity will not be made public during any part of the claims process. You can get a Claim Form at www.SuboxAntitrust.com or by calling 1-877-311-3735 or writing to the address below and requesting a Claim Form. Claim Forms must be received (if submitted online) or postmarked (if mailed) by **February 17, 2024**, and may be submitted online at www.SuboxAntitrust.com or mailed to the address below:

Settlement Administrator 54388
 c/o A.B. Data, Ltd.
 P.O. Box 173080
 Milwaukee, WI 53217

The Settlement Administrator may seek to make the Settlement payments electronically, as this may be the easiest and quickest option for you to receive your money. Please ensure you provide a current, valid email address and mobile phone number with your claim submission. If the email address or mobile phone number you include with your submission becomes invalid for any reason, it is your responsibility to provide accurate contact information to the Settlement Administrator to receive payment.

QUESTIONS? CALL 877-311-3735 OR VISIT WWW.SUBOXANTITRUST.COM.

8. How much will my payment be?

Each End Payor Class member's share of the Net Settlement Fund will be based on its qualifying purchases of Suboxone, and its AB-rated generic equivalents, and will be determined according to the End Payor Plaintiffs' proposed Plan of Allocation, if approved by the Court. Payments will be based on a number of factors, including but not limited to the number of valid claims filed by all members of the End Payor Class and the dollar value of each member of the End Payor Class's purchases in proportion to the total claims filed. Complete details of how your recovery will be calculated are in the detailed Plan of Allocation, which can be viewed at www.SuboxAntitrust.com.

9. When would I get my payment?

The Court must approve the Settlement and any appeals of that decision must be resolved before any money is distributed to End Payor Class members. The Settlement Administrator must also complete processing of all the Claim Forms and determine distribution amounts. This process can take several months.

EXCLUDING YOURSELF FROM THE END PAYOR CLASS

10. What does it mean to request to be excluded from the End Payor Class?

If you do not want to be part of the End Payor Class and want to keep your right to sue Indivior relating to the allegations concerning the alleged anticompetitive conduct described in this Notice, then you must take steps to remove yourself from the End Payor Class. This is called excluding yourself, or "opting out" of the End Payor Class. If you exclude yourself, you will not be eligible to receive any payment from the Settlement in this lawsuit, and you will not be bound by any judgment rendered for or against Indivior.

11. How do I exclude myself from the End Payor Class?

To exclude yourself from the End Payor Class, you must send a letter by mail stating that you wish to be excluded from the End Payor Class in *In Re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation*, 2:13-md-02445-MSG. Be sure to include your name, address, telephone number, and signature. TPPs must also provide data sufficient to prove End Payor Class membership. You cannot exclude yourself over the telephone. Consumer identities will not be made public as part of the exclusion process. The Settlement Administrator, the Court, Class Counsel, and Defense Counsel will keep that information confidential. End Payor Class members are not permitted to exclude other End Payor Class members. In addition, group or class-wide exclusions are not permitted. You must mail your Request for Exclusion, postmarked no later than **October 12, 2023**, to:

Settlement Administrator 54388
 ATTN: EXCLUSIONS
 P.O. Box 173001
 Milwaukee, WI 53217

You may also email your exclusion request to info@SuboxAntitrust.com. Any email exclusion requests must also be submitted no later than **October 12, 2023**.

12. If I don't exclude myself, can I sue for an antitrust violation later?

No. Unless you exclude yourself, you give up the right to sue Indivior for the same issues in this case. You must exclude yourself from the End Payor Class to be able to bring your own, separate lawsuit(s) on all issues against Indivior. Remember, the exclusion deadline is **October 12, 2023**.

QUESTIONS? CALL 877-311-3735 OR VISIT WWW.SUBOXANTITRUST.COM.

OBJECTING TO THE SETTLEMENT

You can tell the Court that you do not agree with any part of the Settlement and/or Co-Lead Counsel's request for attorneys' fees, reimbursement of expenses, or the request for service awards to the named End Payor Plaintiffs by filing an objection.

13. How do I tell the Court what I think about the Settlement?

If you are an End Payor Class Member, you can ask the Court to deny approval of the Settlement by filing an objection. You may tell the Court that you object, entirely or in part, to the Settlement and/or Co-Lead Counsel's request for attorneys' fees, reimbursement of expenses, or End Payor Plaintiffs' request for service awards. You cannot ask the Court to order a different settlement; the Court can only approve or reject the proposed Settlement. If the Court denies approval, no Settlement payments will be sent out and the lawsuit against the Defendant will continue. If that is what you want to happen, you must object. You may also ask the Court to speak in person at the Fairness Hearing.

To object, you must prepare and sign a written objection that includes: (i) the case name and number ("In Re: Suboxone (Buprenorphine Hydrochloride and Nalaxone) Antitrust Litigation, Civil Action No. 2:13-md-02445"); (ii) your full name, current address, and telephone number; (iii) a written statement of your objections and the specific reasons for each; (iv) any supporting papers, evidence, or documents; (v) a statement of whether you intend to appear and present your objections at the Fairness Hearing (see **Question 20**); and (vi) your signature. You must send your objection no later than **October 5, 2023**.

If you are an individual consumer, and do not want your identity to be put on the public record as part of the objection process, send your objection to the Settlement Administrator at Settlement Administrator 54388. OBJECTIONS, c/o A.B. Data, Ltd., P.O. Box 173080. Milwaukee, WI 53217. The Settlement Administrator will redact (black out) your name, address, and telephone number and then file the redacted objection on the public court docket. The Settlement Administrator will also send a copy of the original, unredacted objection to the Judge, Co-Lead Counsel, and Indivior's counsel, all of whom will keep your identifying information confidential.

If you do not care to keep your identity off the public record as part of the objection process, send your objection to Co-Lead Counsel and the Court at the addresses below, and the Clerk will place the objection, with the identifying information, on the public docket. How the Judge and the parties treat the merits of your objection does not depend on whether you keep your identifying information off the public record. The choice is entirely yours.

Co-Lead Counsel			
Marvin A. Miller Miller Law LLC 145 S. Wells St., 18 th Floor Chicago, IL 60606	Kenneth A. Wexler Wexler Boley & Elgersma LLP 311 S. Wacker Dr., Suite 5450 Chicago, IL 60606	Steve Shadowen Hilliard Shadowen LLP 1135 W. 6 th Street, Suite 125 Austin, TX 78703	Michael Buchman Motley Rice LLC 777 Third Avenue, 27 th FL New York, NY 10017
Court			
U.S. District Court for the Eastern District of Pennsylvania James A. Byrne U.S. Courthouse 601 Market Street Philadelphia, PA 19106			

QUESTIONS? CALL 877-311-3735 OR VISIT WWW.SUBOXANTITRUST.COM.

IF YOU DO NOTHING

14. What happens if I do nothing at all?

If you are an End Payor Class member and you do nothing, you will remain in the End Payor Class and be bound by the decision in the action and on the Settlement, but you may not participate in the Settlement as described in this Notice, if the Settlement is approved. To participate in the Settlement, you must complete, sign, and return the Claim Form before the claims filing deadline provided on the Claim Form and on the Settlement website to be eligible to receive a payment.

THE LAWYERS REPRESENTING THE END PAYOR CLASS

15. Do I have a lawyer in this case?

The law firms listed below have been appointed by the Court as Co-Lead Counsel. Co-Lead Counsel are experienced in handling similar cases against other pharmaceutical companies. Co-Lead Counsel are:

Co-Lead Counsel	
Marvin A. Miller Miller Law LLC 145 S. Wells St., 18 th Floor Chicago, IL 60606	Kenneth A. Wexler WEXLER BOLEY & ELGERSMA LLP 311 S. Wacker Dr., Suite 5450 Chicago, IL 60606

The law firm listed below represents the Defendant:

Defense Counsel
Justin W. Bernick Hogan Lovells US LLP 555 13th St NW Washington, D.C. 20004

You will not be personally charged for the services of these lawyers in litigating this case against the Defendant.

16. Should I hire my own lawyer?

You do not need to hire your own lawyer because the lawyers appointed by the Court are working on your behalf. You may hire a lawyer and enter an appearance through your lawyer at your own expense if you so desire.

17. How will the lawyers be paid?

If the Court approves the Settlement, Co-Lead Counsel will ask the Court for an award of attorneys' fees of one-third (1/3) from the Settlement Fund (plus a proportionate share of the interest on any portion of the funds deposited in escrow pursuant to Court Order), and reimbursement of litigation expenses incurred in the case. Co-Lead Counsel will also ask for service awards in the sum of \$15,000 for each of the named End Payor Plaintiffs to be paid from

QUESTIONS? CALL 877-311-3735 OR VISIT WWW.SUBOXANTITRUST.COM.

the Settlement Fund for their efforts to date on behalf of the End Payor Class. Co-Lead Counsel may also request additional attorneys' fees and reimbursement of expenses in connection with the administration and preservation of the Settlement Fund. If the Court grants Co-Lead Counsel's requests, these amounts would be deducted from the Settlement Fund. You will not have to pay these fees, expenses, and costs out of your own pocket. The administrative expenses for the Settlement will also be paid out of the Settlement Fund.

Co-Lead Counsel's request for an award of attorneys' fees, reimbursement of expenses, and for service awards for the End Payor Plaintiffs will be filed with the Court and made available for download or viewing on or before September 4, 2023, on the Settlement website, and at the office of the Clerk of the United States District Court for the Eastern District of Pennsylvania, U.S. District Court for the Eastern District of Pennsylvania, James A. Byrne U.S. Courthouse, 601 Market Street, Philadelphia, PA 19106, which can be visited between 9:00 a.m. and 4:00 p.m., Monday through Friday, excluding Court holidays. You can tell the Court you do not agree with Co-Lead Counsel's request for attorneys' fees and expenses, or for service awards for the End Payor Plaintiffs, by filing an objection as described in **Question 13**.

THE FAIRNESS HEARING

The Court will hold a hearing to decide whether to approve the Settlement. You may attend and you may ask to speak, but you do not have to.

18. When and where will the Court decide whether to approve the Settlement?

The Court will hold a Fairness Hearing at **1:30 p.m. on October 19, 2023**, before Judge Mitchell S. Goldberg in Courtroom 17A at the U.S. District Court for the Eastern District of Pennsylvania, at the James A. Byrne U.S. Courthouse, 601 Market Street, Philadelphia, PA 19106. At this hearing, the Court will consider whether the Settlement is fair, reasonable, and adequate. If there are objections, the Court will consider them. After the hearing, the Court will decide whether to give final approval to the proposed Settlement. We do not know how long the decision will take.

The time and date of the Fairness Hearing may change without additional mailed or publication notice. For updated information on the hearing, visit www.SuboxAntitrust.com.

19. Do I have to come to the hearing?

No. Co-Lead Counsel will answer questions posed by the Court. But you are welcome to attend the hearing at your own expense. If you send an objection, you do not have to appear in Court to talk about it; as long as you mail your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but it is not necessary. Attendance is not necessary to receive a *pro rata* share of the Settlement Fund, provided you submitted a valid and timely Claim Form.

20. May I speak at the hearing?

You may ask the Court for permission to speak at the Fairness Hearing, either in person or through your own attorney, if you file a request to speak in person. *See Question 13.* If you appear through your own attorney, you are responsible for paying that attorney.

GETTING MORE INFORMATION

21. Are more details available?

For more detailed information about this litigation, please refer to the papers on file in this litigation, which may be inspected at the Office of the Clerk, United States District Court for the Eastern District of Pennsylvania, James A. Byrne U.S. Courthouse, 601 Market Street, Philadelphia, PA 19106 during regular business hours of each business day. You may also get additional information by writing to Co-Lead Counsel as indicated above (*See Question 15*), by visiting www.SuboxAntitrust.com (which provides copies of some key pleadings), or by contacting the Settlement Administrator, A.B. Data, Ltd., at the following:

Settlement Administrator 54388
c/o A.B. Data, Ltd.
P.O. Box 173080
Milwaukee, WI 53217
1-877-311-3735
info@SuboxAntitrust.com

PLEASE DO NOT WRITE TO OR CALL THE COURT OR THE CLERK'S OFFICE FOR INFORMATION. INSTEAD, PLEASE DIRECT ANY INQUIRIES TO THE SETTLEMENT ADMINISTRATOR OR TO CO-LEAD COUNSEL LISTED ABOVE IN QUESTION 15.

DATED: AUGUST 28, 2023

**BY ORDER OF THE UNITED STATES DISTRICT COURT FOR
THE EASTERN DISTRICT OF PENNSYLVANIA**